Belgium’s UCB Names CEO-Elect, Highlights R&D In SLE, Osteoporosis
This article was originally published in The Pink Sheet Daily
Executive Summary
With its new CEO-designate named a week ago and a promising pipeline of early- and late-stage products, Belgium’s mid-sized European pharmaceutical company UCB wants to move beyond patent cliffs and restructuring to concentrate on the potential of its R&D.